HMG (Human Menopausal Gonadotropin) Research Guide: FSH & LH Activity, HPG Axis & Reproductive Studies

Human menopausal gonadotropin (hMG), also known as menotropins, is a purified gonadotropin preparation derived from the urine of postmenopausal women. It contains both follicle-stimulating hormone (FSH) and luteinizing hormone (LH) activity, making it a dual-gonadotropin research compound with significant roles in reproductive endocrinology, fertility research, and hypothalamic-pituitary-gonadal (HPG) axis studies. This guide reviews hMG’s composition, mechanisms of action, research applications, and its relevance in both female and male reproductive science. All content is for informational and research purposes only.

What Is HMG?

Human menopausal gonadotropin is a biological extract standardized to contain defined ratios of FSH and LH activity, historically in a 1:1 FSH:LH ratio, though modern highly purified preparations (HP-hMG) maintain this ratio with greater consistency and reduced urinary protein contaminants. The most recognized commercial forms include Menopur® (Ferring Pharmaceuticals) and Merional®, both used clinically in fertility medicine.

hMG differs from recombinant FSH (rFSH) preparations in that it contains both FSH and LH activity. This distinction is clinically and scientifically significant because LH plays a critical complementary role to FSH in gonadal stimulation, particularly in the two-cell, two-gonadotropin model of follicular steroidogenesis in females, and in Leydig cell testosterone production in males.

Mechanism of Action

FSH Component

The FSH component of hMG binds to FSH receptors (FSHR) on granulosa cells in the female ovary and Sertoli cells in the male testes. In females, FSH stimulates follicular development, granulosa cell proliferation, and aromatase activity, converting androgens to estradiol. In males, FSH drives spermatogenesis by supporting Sertoli cell function and maintaining the seminiferous tubule environment required for sperm development.

LH Component

The LH component binds to LH receptors (LHR) on theca cells in females and Leydig cells in males. In females, LH stimulates theca cell androgen production (androstenedione and testosterone), which granulosa cells then aromatize to estradiol, the “two-cell, two-gonadotropin” model. In males, LH binding to Leydig cells drives testosterone biosynthesis via the StAR/P450scc/3β-HSD pathway.

Synergistic Gonadotropin Effects

The combined FSH+LH activity of hMG produces synergistic gonadal stimulation that neither hormone achieves alone. Research has demonstrated that optimal follicular development in females and optimal spermatogenesis in males require both gonadotropins in appropriate ratios, which is why hMG preparations with maintained FSH:LH balance are valued in reproductive research and clinical fertility protocols.

Research Applications

Female Reproductive Research: Ovarian Stimulation

hMG is extensively used in controlled ovarian stimulation (COS) research for in vitro fertilization (IVF) and other assisted reproductive technologies (ART). Studies comparing hMG to recombinant FSH protocols have demonstrated that hMG-stimulated follicles produce oocytes with comparable or slightly improved developmental competence, proposed to be related to the LH-driven androgen priming of granulosa cells that enhances FSH receptor expression and follicular sensitivity.

A 2012 Cochrane meta-analysis (van Wely et al.) covering 14 RCTs and 2,062 participants found that hMG was associated with a modest but statistically significant improvement in live birth rate compared to rFSH in IVF cycles (OR 1.20, 95% CI 1.01–1.42), though effect sizes varied across studies. This finding has continued to drive research interest in the role of LH activity in COS outcomes.

Male Hypogonadotropic Hypogonadism Research

In males, hMG is an important research tool and clinical agent for hypogonadotropic hypogonadism (HH), a condition in which the pituitary fails to produce sufficient FSH and LH, resulting in low testosterone and impaired spermatogenesis. Because HH is pituitary-origin (secondary hypogonadism), the testes remain responsive to gonadotropin stimulation. Research protocols using hMG combined with hCG (to provide sustained LH-like activity) have demonstrated restoration of spermatogenesis and fertility in HH patients, including those with Kallmann syndrome.

HPG Axis Modulation Research

Beyond fertility applications, hMG serves as a research tool for studying HPG axis dynamics. Exogenous gonadotropin administration allows researchers to dissect the relative contributions of FSH vs. LH to gonadal function, steroidogenesis, and gametogenesis in animal models and human studies. hMG is used in GnRH deficiency models to determine the minimum gonadotropin requirements for spermatogenesis or folliculogenesis.

Post-Cycle and Gonadal Suppression Research

In androgen research contexts, hMG has been studied as a gonadal recovery agent following suppression of the HPG axis. Exogenous androgens suppress endogenous LH and FSH secretion via negative feedback, leading to testicular atrophy and suppressed spermatogenesis. Research into gonadal recovery protocols has evaluated hMG as a combined FSH+LH stimulus to accelerate restoration of Leydig cell and Sertoli cell function during the recovery period.

HMG vs. Related Gonadotropin Research Compounds

Key Research Findings Summary

• IVF outcomes: hMG associated with modestly higher live birth rates vs. rFSH in meta-analyses, attributed to LH-driven androgen priming of follicles
• Spermatogenesis: Combined hMG + hCG protocols induce spermatogenesis in the majority of HH males, with sperm counts improving over 12–24 month treatment periods
• Endometrial receptivity: Some research suggests LH activity during stimulation may improve endometrial development via progesterone priming, potentially improving implantation
• HP-hMG purity: Highly purified hMG (HP-hMG) preparations show equivalent efficacy to standard hMG with reduced immunogenic urinary protein load, relevant to research requiring consistent, well-characterized preparations

Research and Storage Notes

hMG is a lyophilized protein preparation that requires reconstitution with the provided sterile diluent prior to use. Reconstituted solutions should be used promptly and stored refrigerated (2–8°C) for no more than 24–48 hours. Lyophilized powder is stored at 2–25°C, protected from light and moisture. As a urinary-derived biological, lot-to-lot consistency is an important quality parameter; HPLC characterization of FSH:LH activity ratios and purity should be confirmed from supplier documentation.

Disclaimer

HMG is a regulated biological agent with clinical applications under physician supervision. It is referenced here strictly for scientific and educational purposes related to reproductive endocrinology and HPG axis research. This content does not constitute medical advice, and hMG should only be used in contexts compliant with applicable regulations.

References

• van Wely M, et al. (2012). Recombinant versus urinary gonadotrophin for ovarian stimulation in assisted reproductive technology cycles. Cochrane Database of Systematic Reviews, Issue 2. CD005354.
• Balasch J, Fábregues F. (2002). LH in the follicular phase: neither too much nor too little. Human Reproduction Update, 8(4), 406–412.
• Pitteloud N, et al. (2002). The relative role of gonadal sex steroids and gonadotropin-releasing hormone pulse frequency in the physiological regulation of follicle-stimulating hormone secretion. Journal of Clinical Endocrinology & Metabolism, 87(4), 1520–1527.
• Buchter D, et al. (1998). Pulsatile GnRH or human chorionic gonadotropin/human menopausal gonadotropin as effective treatment for men with hypogonadotropic hypogonadism. European Journal of Endocrinology, 139(3), 298–303.

Research-Grade HMG Available

Exceed Enhancement offers research-grade HMG for qualified research applications. View product specifications and ordering information →